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Head and neck squamous cell cancer (HNSCC) is one of the top ten cancers in the United States. The survival rate of HNSCC has
only marginally improved over the last two decades. In addition, African-American men bear a disproportionate burden of this
preventable disease. Therefore, a critical challenge of preventive health approaches is warranted. Salvianolic acid B (Sal-B) isolated
from Salvia miltiorrhiza Bge, which is a well-know Chinese medicines has been safely used to treat and prevent aging diseases
for thousand of years. Recently, the anticancer properties of Sal-B have received more attention. Sal-B signiﬁcantly inhibits or
delays the growth of HNSCC in both cultured HNSCC cells and HNSCC xenograft animal models. The following anticancer
mechanisms have been proposed: the inhibition of COX-2/PGE-2 pathway, the promotion of apoptosis, and the modulation
of angiogenesis. In conclusion, Sal-B is a potential HNSCC chemopreventive agent working through antioxidation and anti-
inﬂammation mechanisms.
1. HNSCC and Chemoprevention
Over 90% of head and neck cancers are squamous cell
carcinomas (HNSCC). Oral cancer accounts for a major
proportion of HNSCC, which is the sixth most common
cancer worldwide. In the United States, oral and pharyngeal
cancers alone are diagnosed in about 36,540 Americans
annually, and 7,880 are projected to die from these diseases
in 2010 according to the American Cancer Society. HNSCC
has been less studied compared to other cancers and the
incidence of this cancer has not shown any improvement
in the last 20 years (Figure 1) .T h e5 - y e a rs u r v i v a lr a t ef o r
oral and pharyngeal cancers in Caucasian patients is 56%,
while for African American men; it is only 34% [1]. In over
50% of ﬁrst diagnosed cases of HNSCC in African American
men, the cancer has already metastasized to other organs,
such as the lungs. HNSCC prevention, earlier detection, and
viable treatment options are of paramount importance to
reduce the cancer incidence, improve patient outcomes and
diminish the disparity.
HNSCC have been considered to be a typical multistep
carcinogenesis with stepwise accumulations of genetic alter-
ations resulting in aberrant cellular appearance, deregulated
cell growth and carcinoma [2]. Patients with early stages of
disease still have high risk to develop a second malignancy.
A normal epithelial cell can take many years to undergo
the multiple cellular and genetic alterations that lead to
malignant changes. Thus, it remains an appealing strategy
to develop eﬀective, nontoxic and aﬀordable novel phar-
macological agents for preventing development of HNSCC
a n ds e c o n dp r i m a r yH N S C C[ 2–5]. Chemoprevention has
been considered a rational and appealing strategy to prevent
or delay the development of HNSCC, additionally; dietary
nutrients such as green tea, β-carotene and vitamin E
have been also used as preventive agents [5–8]. Extensive
studies have suggested that green tea, one of the most
commonly consumed beverages worldwide, can reduce the
risk of HNSCC development by inducing antioxidative
activity via apoptosis and inhibiting epidermal growth factor
receptor related signaling pathway [7, 9, 10]. There have
been an increased number of case reports that high doses
of green tea beverages cause hepatotoxicity [11]. Both
vitamin E and β-carotene revealed the growth-inhibitory
eﬀect against lung cancer in cell culture and rodent mod-
els. But the promising activities have not translated into
clinical success. Indeed, these supplements may actually2 Journal of Oncology
lead to unexpected detrimental eﬀects in humans as well
as beneﬁcial eﬀects [12, 13]. Hence, the crux is to ﬁnd
an eﬀective, nontoxic and aﬀordable novel pharmacological
agent in clinical trials for preventing carcinogenesis and
the development of HNSCC as well as second primary
HNSCC.
2. SalvianolicAcidB
Radix Salviae miltiorrhizae (danshen or tanshen), the dried
root of Salvia miltiorrhiza Bge is very important and popular
in traditional Chinese medicine. It that has been widely
and successfully used treating and preventing aging diseases,
such as cardiovascular and cerebrovascular diseases, and
cancers for thousand years and is ranked as a “Super grade”
drug recorded in Shen-Nung’s Pen-Ts’ao [14]. Currently,
danshen has been accepted and used in Japan, the United
States and some European countries [14–16]. In the last 50
years, Danshen received more attention by modern scientists
that more than 70 compounds, including the hydrophilic
depsides derivatives and the lipophilic diterpenoids, have
been isolated from the Danshen herb [16, 17]. Salvianolic
acid B (Sal-B) is the most abundant and bioactive member
of the hydrophilic components in Danshen. Therefore, Sal-B
is used as a quality control ingredient and active marker for
S. miltiorrhiza Bge products by the National Pharmacopoeia
Council of China. Sal-B contains seven phenolic hydroxyls
which have been found to be closely related to redox
potentials and/or antioxidant activities [18]. The structure
of Sal-B is depicted in Figure 2. Sal-B has been studied for
its preventive eﬀects against cancer as well as cardiovas-
cular, neurodegenerative, and other diseases [19–23]. The
mechanisms mainly contribute to its antiinﬂammatory and
antioxidative properties, modulation of apoptosis, inhibition
of platelet aggregation, improved coronary microcirculation,
as well as, regulation of angiogenic processes [14, 24, 25]. We
will introduce the function and biological activities of Sal-B,
validate its eﬃcacy on HNSCC, and discuss the foreground
of this component.
3.AntiinﬂammatoryActivities
It appears that there is a general concept that chronic
inﬂammation characterized by continued active inﬂamma-
tion responses and tissue destruction, can be a major cause
of cancers and occur during the aging process [26–28].
Mounting studies have reported that Sal-B is capable of
preventing the development of cancer; and the possible
antiinﬂammatory mechanisms of Sal-B involve modulat-
ing cytokines, Cyclooxygenase-2/prostaglandin E2 (COX-
2/PGE-2) pathway [24, 25, 29], NF-κB[ 30–32], TNF-α [33–
35]a n dM M P s[ 36–38]. Numbers of clinical experiences
indicate its eﬀectiveness and safety in contrast to the disad-
vantages of nonsteroidal antiinﬂammatory drugs (NSAIDs).
NSAIDs,usedprimarilytotreatinﬂammation,areassociated
with several serious side eﬀects including gastrointestinal
discomfort, cardiovascular disease and kidney failure [39–
42].
3.1. COX-2/PGE-2. COX-2, an inducible form of cyclooxy-
genase is undetectable in most normal tissues, but abundant
in the pathogenesis of inﬂammatory and neoplastic diseases.
Additionally, its principal metabolite PGE2 has pleiotropic
eﬀects such as promoting cell proliferation, inhibiting
cell death, promoting tumor angiogenesis, and decreasing
immunosurveillance. Sal-B has been reported to attenuate
signiﬁcantly COX-2 expression and PGE2 production with
or without lipopolysaccharide (LPS)-induced both in vitro
and in vivo [24, 25, 29], and which may be attributed to
the downregulation of JNK and ERK phosphorylation and
blockage of MAPKs phosphorylation [29].
3.2. NF-κB. NF-κB, a protein complex that controls the
transcription of DNA, regulates cellular responses as a ”ﬁrst
responder” to harmful cellular stimuli, and its aberrant
expressionislinkedtocancerandinﬂammation[43].Several
experiments clariﬁed that the antiinﬂammatory eﬀects of
Sal-B depend on the inhibition of the NF-κB signaling
pathway [30–32]. Moreover, Sal-B attenuates the expression
of VCAM-1 and ICAM-1 in TNF-α stimulated human aortic
endothelialcellbypartialblockageofNF-κB expression [34].
3.3. TNF-α. Tumor necrosis factor-alpha (TNF-α) ,ar e p r e -
sentative proinﬂammatory cytokine damages cell structure
and increases endothelial permeability and is involved in sys-
temic inﬂammation [44]. Sal-B has showed to signiﬁcantly
reduced the production of TNF-α induced by LPS treatment
in rat primary microglia in a dose-dependent manner [32].
In addition, Sal-B protects endothelial cell against TNF-α
disruption by inhibiting vascular endothelial growth factor
(VEGF) and extracellular signal-regulated kinase (ERK)
activation [45].
3.4. MMPs. Matrix metalloproteinases (MMPs), inﬂamma-
tory mediators are expressed in vascular cells in the course
of atherosclerosis [46]. Sal-B treatment eﬀectively inhibits
MMP-2 and MMP-9 activitation and expression both cell
culture and animal models, and it also, downregulates
JNK and ERK phosphorylation [36, 37]. Some researchers
found Sal-B could suppress high glucose-induced mesangial
cells proliferation and extracellular matrix production in
a dose-dependent manner, partially through modulating
the cell-cycle progress and MMP-2 and MMP-9 activities
[30, 31].
4.AntioxidativeActivities
A vast amount of evidence suggests that overproduction
of reactive oxygen species (ROS) and reactive nitrogen
species (RNS) can damage cellular lipids, inhibit the normal
function of proteins or DNA, and are associated with
the pathogenesis of atherosclerosis, cardiovascular diseases,
hypertension, ischemia/reperfusion injury, neurodegenera-
tive diseases, and cancer [47, 48]. Sal-B, as an antioxidant
neutralizes direct ROS attacks and terminates free radical-
mediated oxidative reactions to protect the human body
from such diseases [49].Journal of Oncology 3
4.1. Radical Scavenging. Reactive oxygen species (ROS),
such as superoxide anion, hydroxyl radicals and hydrogen
peroxide are chemically reactive molecules derived from
oxygen.Theyusuallycontainoneormoreunpairedelectrons
in the atomic or molecular orbital [50]; therefore, they can
easily participate in redox reactions and they play a crucial
role in biological systems [51, 52]. Excess ROS can disturb
the equilibrium status of prooxidant/antioxidant reactions,
leading to the disruption of cellular functions in contrast
to low/moderate concentrations that occur in response to
induction of a mitogenic reaction and normal function of
several cellular signaling pathways [53, 54]. There is increas-
ing evidence that Sal-B has the capability to scavenging
free radicals including superoxide anion, hydroxyl, DPPH
(1,1-diphenyl-2-picryl-hydrazyl) and ABTS (2-azino-bis(3-
ethylbenzthiazoline-6- sulfonic acid)) radicals in addition to
hydrogen peroxide due to redox properties of the phenolic
structure [55]. Sal-B showed a high antioxidant capacity
in terms of neutralizing free radicals, as well as exhibiting
signiﬁcantly higher scavenging activity than l-Ascorbic acid
(vitamin C) [56, 57]. 50% radical scavenging activity at a
concentration of the Sal-B lower ∼50% and ∼40% than
Vitamin C in DPPH and ABTS assays, respectively (1.81 ±
0.01 versus 3.44 ± 0.03μg/ml, 1.43 ± 0.01 versus 2.50 ±
0.02μg/ml) [57].
4.2.AntioxidantActivities. Freeradicalshavebeenelucidated
to cause oxidative damage to cellular components, including
attacks on DNA, oxidation of proteins and production
of lipid peroxidation, these processes lead to disorder in
cellular, tissue and organ function [52, 58, 59]. Sal-B has
been reported to be a powerful and eﬀective antioxidant,
not only reducing lipid peroxidation, but also rescuing
the loss of antioxidant enzyme activities against ﬁbrosis
and ischemia-reperfusion injuries [60, 61]. Some studies
have reported that Sal-B can protect the brain and heart
from ischemia-reperfusion injury by improving the recovery
of motor function via regulating energy metabolism and
maintaining the balance of free radicals such as SOD, GSH,
and ATP levels against lipid peroxidation and superoxide
anion production [62–65]. In the hepatic stellate cells
(HSCs), Sal-B exerts suppressive eﬀects on ROS to inhibit
the proliferation and lipid peroxidation of HSCs through
inhibiting NADPH oxidase and TGF-β1s e c r e t i o n[ 49, 66,
67]. Studies have shown that ROS leads to the oxidation
of low-density lipoproteins and accumulates within plaques
and contributes to the atherosclerosis [66, 68]. Sal-B was
identiﬁed to be a potent antioxidant, endothelial-protecting
agent, an inhibitor that suppresses the expression of ICAM
and VCAM, capable of inhibiting LDL oxidation and also
inhibits ox-LDL induced endothelial injuries [69]. In sum,
the antioxidative properties of Sal-B are closely associated
w i t hi t sp r o t e c t i v ee ﬀect of aging diseases [70].
5. HNSCCand Sal-B
Cancers have a close and delicate relationship with inﬂam-
mation [26, 71, 72]. Inﬂammation often exists in the tumor
microenvironment and is induced by inﬂammatory medi-
ators produced by the tumor [73–75]. HNSCCs are highly
inﬂammatoryandaggressive,andtheyoverexpressanumber
of inﬂammatory mediators such as COX-2, EGFR, VEGF
and MMPs [76–78]. Sal-B, as chemopreventive agent exerts
its eﬀects by inhibiting tumor initiation and development;
itsanticarcinogenicactivitieshavebeenclearlydemonstrated
in both cell cultures and animal models [24]. Furthermore,
research has also shown that the combining Sal-B with
other preventive agents is more eﬀective than single-agent
chemoprevention [25].
We tested the anticancer function of Sal-B in ﬁve human
HNSCC cell lines (JHU-6, JHU-11, JHU-13, JHU-22 and
JHU-29) that Sal-B signiﬁcantly inhibit the cell growth in
cultured cells [24]. In the animal experiments, HNSCC solid
tumorvolumeinSal-Btreatedgroupweresigniﬁcantlylower
than those in untreated control groups [24]. The outcome
is consistently obtained in human breast and prostate
cancer cell lines. We found that Sal-B selectively suppresses
COX-2-related mRNA and protein expression instead of
housekeeping enzyme of COX-1 in the presence or absence
of LPS stimulation. It seems that the chemopreventive eﬀects
of Sal-B depend on COX-2 expression levels, the higher the
expression of COX-2 the more sensitive is Sal-B HNSCC
cell growth-inhibition and PGE2 reduction. In addition, Sal-
B induced caspase-dependent apoptosis by cleavage of a
caspase substrate, poly (ADP) ribose polymerase (PARP).
Sal-B also decreased the cellular amounts of antiapoptotic
proteins such as NF-κB, MDM-2, Bcl-2 and Bcl-xL and
increased proapototic proteins such as p53 and caspase 3
[24,79].Themechanismofcancer-preventionwasattributed
to the COX-2/PGE2 inhibition and apoptotic pathway
induction. PGE2, one of important prostaglandin product of
COX-2 is involved in chronic inﬂammation [80].
A promising strategy to enhance the cancer-preventive
eﬃcacyistousetwoanticanceragentsincombination,which
may produce synergy and lower the dose required for each
agent [79, 81]. Celecoxib, a selective COX-2 inhibitor has
been reported to have cancer-preventive eﬀects in various
types of cancers including HNSCC [82]. However, it was
found to be associated with a dose-dependent cardiovascular
morbidity that limited its long-term use. Hence, we decided
to use Sal-B combined with low-dose celecoxib in order
to increase the anticancer eﬃcacy and reduce drug side
eﬀects. The outcome showed that the combination of half-
dose of Sal-B and celecoxib greatly enhanced the inhibition
of HNSCC cell proliferation compared with either Sal-
B or celecoxib alone both in cell culture (JHU-06, JHU-
011, JHU-013 and JHU-022) and tumor xenografts. The
combination was associated with profound inhibition of
the COX-2/PGE2/EGFR pathways, enhanced induction of
apoptosis, and reduced the side eﬀects of celecoxib due to
dose reduction at the same time [25].
The anticancer eﬀects of Sal-B were also found in 7,12-
dimethylbenz-[a]anthracene-(DMBA) induced oral carcino-
genesis in hamsters [83]. Experiments showed that Sal-B
treatment signiﬁcantly decreased the oral cancer incidence.
Antiangiogenesis may be one of the possible mechanisms
of inhibiting malignant transformation of oral precancerous4 Journal of Oncology
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Figure 2: Chemical structure of Salvianolic acid B.
[75, 84]. The formation of microvessels, and the expression
of proangiogenic factors HIF1α and VEGF, was inhibited by
Sal-B.
Recently, we were inclined to accept the concept that
the prevention is better than a cure. Actually, prevention
is more valuable to reduce the incidence of HNSCC than
i n c r e a s es u r v i v a lr a t e[ 85, 86]. Anticancer properties of Sal-
B are able to prevent and delay the malignant conversion
of premalignant lesions and/or cell growth via inhibition of
inﬂammation and angiogenesis and reduction of apoptosis
(Figure 3).
6. Problem and Future Prospects
Sal-B as a popular compound of Traditional Chinese
Medicine has been studied for its preventive eﬀects against
HNSCC. Most of the proposed beneﬁcial eﬀects have been
attributed to antioxidative and antiinﬂammatory eﬀects. It
is known that the relationships among oxidation, inﬂam-
mation and cancer are considered to be extremely complex.
Firstly, chronic inﬂammation increase the risk of developing
many types of cancer including HNSCC, and inﬂammatory
Sal-B
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Figure 3: Possible anticancer activites of Salvianolic acid B.
cells, chemokines and cytokines are present in the microen-
vironmentofalltumors[71]. Secondly, ROS, an endogenous
class of carcinogens trigger the mutation of the cells have
been demonstrated in the principal step of carcinogenesis
and contribute to cancer progression. Moreover, cancer cells
frequently produce more ROS than normal cells [87, 88].
Thirdly, activated inﬂammatory cells generate ROS and
reactive RNS in response to proinﬂammaory stimuli, which
can function as chemical eﬀectors in inﬂammation-driven
carcinogenesis; ROS-induced oxidations are implicated in
inﬂammation via regulation signal pathways and related
e n z y m e ss u c ha sC O X - 2[ 88, 89]. Sal-B, a natural anticar-
cinogenic agent with antiantioxidant and antiinﬂammatory
activities, reacts easily with free radicals and inhibits eﬀec-
tively COX-2/PGE-2 pathway as well as regulating related
cell signal pathways. It is diﬃcult to distinguish which
is determines prevention to HNSCC because oxidation,
inﬂammation and cancer are intertwined in a complex
web. Sal-B has been showed a signiﬁcant advantage for the
preventionandtreatmentinHNSCCduetoeﬀectivenessand
nontoxic nature.
The discovery of Sal-B anticancer properties is followed
a path of from “bed” to “bench”. A thousand years clinical
practices demonstrate that Danshen is able to eﬀectively
and safely prevent and treat aging diseases, such as cardio-
vascular diseases and cancers. The mechanism studies of
Danshen have been concerned until latest 50 years. Sal-B
is a most abundant and bioactive member of hydrophilic
components in Danshen. The same as Danshen, Sal-B is
a safer agent with no major side eﬀects [20]. Due to our
aging society, both cancer and cardiovascular diseases have
increasingly become the two major killers and human health
hazards. In recent years, the amount of cytotoxic agents
and targeted therapies used to treat HNSCC, include classic
chemotherapeutic agents, chemoprevention agents such as
COX-2 inhibitors, monoclonal antibodies targeting tyrosine
kinase receptors, small molecule tyrosine kinase inhibitors,
and antiangiogenic drugs [90]. Unfortunately, these result
in cardiovascular toxicity. Especially, celecoxib, a selective
COX-2 inhibitor has been required restricted use owing to
its potential to eﬀects the cardiovascular system in long-
term use by the Food and Drug Administration and was
announced the early cessation of a cancer-prevention clinical
trial. It is hailed that Sal-B is a not only cancer-preventive
agent but an also cardiovascular protective agent. Sal-B
inhibits cancer cell proliferation in vitro and in vivo in
additiontoregulatingthemicroenvironment.InastudywithJournal of Oncology 5
celecoxib,Sal-Bresultedin platelet aggregation,playing akey
roleincardiovascularprotection[20].SinceSal-Bexertsdual
pharmacy characteristics, it will lead to broad applications
in the future. But related-mechanisms are still not fully
understood, we need speciﬁc and profound studies about
Sal-B.
Inaddition,somestudiesalsoreportedSal-Bwasreleased
from nanotechnology samples faster and had increased
antioxidant activity compared to the traditionally-powdered
samples [89, 91, 92]. Combined with chemopreventive
agents of traditional Chinese Medicine will further promote
development of Sal-B.
Wefoundaninterestingandconfusingphenomenonthat
Sal-B showed a distinct attack and protective features in
diﬀerent cell lines. Some studies reported Sal-B protected the
SH-SY5Y neuroblastoma cells, hepatocyte and bone marrow
stem cells against apoptosis by relieving oxidative stress and
modulating the apoptotic process [93–95]; on the other
hand, Sal-B has been revealed to activate apoptosis pathways
in order to inhibit cancer cell proliferation [24, 25]. It
seems to be controversial; whereas, the mechanism of signal
regulation is very complex and therefore the role of Sal-
B depends on the type of cell line, the microenvironment.
Diﬀerent concentrations of ROS showed both the induction
and inhibition in cancer development. To deﬁne an accurate
mechanism of Sal-B, particularly which are Sal-B exact
targets, still calls for more studies and developments.
In conclusion, Sal-B, a natural antiinﬂammatory (selec-
tive COX-2 inhibitor) and antioxidative agent has chemo-
preventive activity on HNSCC; due to its eﬀectiveness and
safety it could have much more commercial value for food
and medicine purposes.
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